A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics has bloomed ...

UniQure shares soared on positive AMT-130 Huntington's disease data, but plunged after the FDA reversed its stance on ...

scientists developed a customized gene therapy consisting of a guide and an mRNA that carried instructions for a base editor ...

Presenters at the AAO 2025 meeting outlined a future for retinal care that reduces patient burden by reconsidering treatment delivery methods.

Embargoed for 9am CET (3am ET) on Monday November 3rdAmgen Ventures-backed AAVantgarde Bio has raised $143 million in series B funding that the Italian biotech will use to | Amgen Ventures-backed ...

Cyclone is a portable gene-switch system that uses acyclovir to reversibly control gene expression with minimal toxicity.

First company to enable precision in vivo genome engineering, combining both cell-specific delivery and programmable, locus-specific gene insertion, with the potential to achieve physiological, durabl ...

A top US regulator plans to unveil a faster approach to approving custom gene-editing treatments, a move designed to unleash a wave of industry investment that will yield cures for patients with rare ...